I love these gummies, they are super tasty & effective
Jung et al., 2022)
Agents such as PT-141 or kisspeptin delivered centrally induce acute changes in desire within hours to days
This is about saving hearts Who qualifies: Adults with established CVD + overweight/obesity (BMI 27 kg/m) The drug: Semaglutide 2.4mg once-weekly subcutaneous injection (GLP-1 RA) Titrated to maintenance dose Adjunct to lifestyle counselling & standard care Why NICE said yes: Reduces risk of MACE (heart attack, stroke, CV death) in this population Cost-effective within NHS thresholds (20,00030,000/QALY) Commercial agreement already in place with NHS The pathway is simple: Assess CVD risk Lifestyle counselling Add semaglutide Monitor This follows SELECT trial data showing ~20% MACE reduction independent of weight loss We are watching GLP-1s redefine cardiovascular medicine in real time From diabetes obesity now primary CV risk reduction Whats next
Semaglutide Clinical Trials: What the Evidence Shows The STEP program consisted of four major trials conducted between 2019 and 2021 involving over 4,500 participants with obesity and overweight conditions
Due to high demand, severe medication shortages, and astronomical out-of-pocket costs in the United States, many patients find it difficult or impossible to access regular care